NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 383 filers reported holding NEKTAR THERAPEUTICS in Q2 2018. The put-call ratio across all filers is 0.42 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $501,000 | -48.5% | 27,500 | +0.5% | 0.01% | -50.0% |
| Q2 2019 | $973,000 | +5.1% | 27,350 | -0.8% | 0.01% | +11.1% |
| Q1 2019 | $926,000 | +16.2% | 27,560 | +13.6% | 0.01% | 0.0% |
| Q4 2018 | $797,000 | -49.6% | 24,260 | -6.5% | 0.01% | -40.0% |
| Q3 2018 | $1,582,000 | +42.3% | 25,948 | +14.0% | 0.02% | +25.0% |
| Q2 2018 | $1,112,000 | – | 22,765 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TIRSCHWELL & LOEWY INC | 588,908 | $7,138,000 | 1.23% |
| Granahan Investment Management | 3,693,956 | $44,771,000 | 1.21% |
| NEA Management Company, LLC | 1,825,600 | $22,126,000 | 1.09% |
| FIC CAPITAL INC | 150,868 | $1,829,000 | 0.75% |
| Rhenman & Partners Asset Management AB | 181,797 | $2,203,000 | 0.66% |
| SOPHROSYNE CAPITAL LLC | 60,200 | $728,000 | 0.64% |
| HARVEY CAPITAL MANAGEMENT INC | 130,400 | $1,580,000 | 0.63% |
| Artal Group S.A. | 1,300,000 | $15,756,000 | 0.57% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 564,418 | $6,840,000 | 0.47% |
| OppenheimerFunds, Inc. | 24,400,000 | $295,728,000 | 0.35% |